Related Experiment Video

Updated: Aug 6, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Targeting Cyclin-Dependent Kinases in Ovarian Cancer

Qi Zhou1

  • 1a Department of Obstetrics and Gynecology , The Affiliate Hospital of Guizhou Medical University , Guizhou , China.

Cancer Investigation
|April 14, 2017
PubMed

Insights

Targeting cyclin-dependent kinases (CDKs) shows promise for treating ovarian cancer, a common gynecological malignancy. Further preclinical research is needed to develop effective CDK-targeting therapies, potentially combined with platinum drugs.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Therapeutics

Background:

  • Ovarian cancer is a leading cause of gynecological cancer mortality, often diagnosed late.
  • Cell cycle dysregulation is a hallmark of cancer, making cell cycle regulators like cyclin-dependent kinases (CDKs) attractive therapeutic targets.
  • CDKs are regulated by cyclins and CDK inhibitors (CKIs), and their dysregulation contributes to cancer progression.

Purpose of the Study:

  • To review the role of cell cycle dysregulation in ovarian cancer.
  • To summarize recent advances in targeting CDKs for ovarian cancer treatment.
  • To discuss future directions for CDK-targeted therapies in ovarian cancer.

Main Methods:

  • Literature review of preclinical and clinical studies on CDK-targeting agents in ovarian cancer.
  • Analysis of the mechanisms of action for various CDK inhibitors.
  • Evaluation of combination strategies, including with platinum-based chemotherapy.

Main Results:

  • Targeting CDKs, particularly in combination with platinum-based drugs, demonstrates significant potential efficacy in preclinical ovarian cancer models.
  • Numerous small molecules, peptides, and immunotherapies targeting CDKs are under investigation.
  • Early-stage preclinical studies suggest promising therapeutic avenues.

Conclusions:

  • Cell cycle dysregulation is critical in ovarian cancer pathogenesis.
  • Targeting CDKs represents a promising strategy for ovarian cancer treatment, especially when combined with conventional therapies.
  • Further preclinical development, including in vivo studies and mechanistic investigations, is essential before human trials can commence.
Keywords:
Cyclin-Dependent KinasesGynecological MalignancyOvarian Cancer

More Related Videos

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells11:37

In vitro Enrichment of Ovarian Cancer Tumor-initiating Cells

Published on: February 18, 2015

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors07:01

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Published on: March 1, 2020

Related Concept Videos

Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...